GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines

Completed

Conditions: Presence of Materials From PCV-1

Interventions: Procedure: Serum sample

First Posted Date: 2012-07-27

Last Posted Date: 2012-07-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01651247

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: belimumab 10mg/kg
Other: placebo

First Posted Date: 2012-07-25

Last Posted Date: 2022-11-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 93

Registration Number: NCT01649765

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers

Phase 1

Completed

Conditions: Hypertension

First Posted Date: 2012-07-24

Last Posted Date: 2017-07-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23

Registration Number: NCT01648231

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Dose Ranging of GSK2336805 in Combination Therapy

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: GSK2336805 40 mg
Drug: GSK2336805 60 mg
Drug: Pegylated interferon alpha-2a
Drug: Ribavirin
Drug: Telaprevir

First Posted Date: 2012-07-24

Last Posted Date: 2017-06-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 286

Registration Number: NCT01648140

Locations: 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: GSK1322322 (mesylate salt) Powder for Injection
Drug: GSK1322322 (freebase) tablets
Drug: GSK1322322 (mesylate salt) Powder for Oral Solution
Drug: GSK1322322 (freebase) tablets FED